论文部分内容阅读
[目的]通过检测乳腺癌病变中PDX-1蛋白及mRNA的表达情况,分析其与乳腺癌临床病理特征及乳腺癌分子亚型之间的关系,探讨其在乳腺癌发生、发展及预后中的作用。[方法]采用免疫组织化学EnVision法及实时定量RT-PCR方法检测乳腺癌、乳腺良性病变及癌旁乳腺组织组织中PDX-1蛋白及mRNA的表达。[结果]PDX-1蛋白在乳腺癌中的表达呈高表达,在癌旁乳腺组织、良性病变组织中基本无表达(P﹤0.01)。PDX-1蛋白的表达与淋巴结转移、分化程度和临床分期有关,与患病年龄、组织学类型、瘤体大小无关(P﹥0.05)。PDX-1蛋白和mRNA在乳腺癌管腔A型和管腔B型中的表达显著高于HER-2过表达型、基底细胞样型和未分类型(P﹤0.05)。实时定量RT-PCR检测的PDX-1mRNA与免疫组化检测的PDX-1蛋白在乳腺癌组中的表达具有一致性。[结论]PDX-1有望成为乳腺癌基因治疗的新靶点及乳腺癌基因分型筛选的新指标。
[Objective] To investigate the relationship between the expression of PDX-1 protein and mRNA in breast cancer and the clinicopathological features and molecular subtypes of breast cancer, and to explore its role in the development, progression and prognosis of breast cancer effect. [Methods] The expression of PDX-1 protein and mRNA in breast cancer, benign breast lesions and adjacent normal breast tissues were detected by EnVision immunohistochemistry and real-time quantitative RT-PCR. [Results] PDX-1 protein was overexpressed in breast cancer and almost no in breast cancer tissues and benign lesions (P <0.01). The expression of PDX-1 protein was correlated with lymph node metastasis, differentiation and clinical stage, but not with age, histological type and tumor size (P> 0.05). The expression of PDX-1 protein and mRNA in breast cancer type A and type B were significantly higher than those in HER-2 overexpression, basal cell type and unsorted type (P <0.05). Real-time quantitative RT-PCR detection of PDX-1 mRNA and immunohistochemical detection of PDX-1 protein expression in breast cancer consistent. [Conclusion] PDX-1 is expected to be a new target of breast cancer gene therapy and a new index of breast cancer genotyping screening.